IP Library › Granted Patent US 7,816,323
Granted Patent B2
US 7,816,323 · App. 12/758,621 · Granted Oct 19, 2010

Methods of using corticotropin-releasing factor for the use of the treatment of cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,816,323
App. No.
12/758,621
Granted
Oct 19, 2010
Kind
B2
Abstract

Provided herein is a method for treating cancer in a human by administering a high dose of corticotropin-releasing factor (CRF).

Claims (15)

1. A method for inhibiting tumor progression in a human patient with cancer, comprising administering human corticotropin-releasing factor (CRF) and bevacizumab to said patient; wherein said administering CRF comprises administering CRF to said patient subcutaneously at least once per day, wherein the cancer is breast cancer or colon cancer.

2. The method of claim 1 , wherein the cancer is metastatic.

3. The method of claim 1 , wherein the method further comprises monitoring tumor progression in the human.

4. The method of claim 1 , wherein said administering CRF comprises administering CRF in a dose between 1 μg/kg to 100 μg/kg of body weight of the patient.

5. The method of claim 1 , wherein said administering CRF comprises administering CRF in a dose of about 1 to about 4 mg.

6. The method of claim 1 , wherein said administering CRF comprises administering CRF in a dose of about 1 mg.

7. The method of claim 1 , wherein said administering CRF comprises administering CRF twice daily to said patient.

8. The method of claim 1 , wherein said administering CRF comprises administering CRF to said patient at least once a day for a period of 2 weeks or more.

9. The method of claim 1 , wherein said administering CRF comprises administering CRF to said patient at least once a day for a period of one month or more.

10. The method of claim 1 , wherein said administering CRF comprises administering CRF to said patient at least once a day for a period of 3 months or more.

11. The method of claim 1 , wherein bevacizumab is administered in a dose between 5 mg/kg and 15 mg/kg of body weight of the patient.

12. The method of claim 1 , wherein bevacizumab is administered in a dose of 10 mg/kg of body weight of the patient.

13. The method of claim 1 , wherein said administering bevacizumab is administered to the patient once a week, every two weeks or every three weeks.

14. The method of claim 1 , wherein the cancer is breast cancer.

15. The method of claim 1 , wherein the cancer is colon cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2011
From: EVANS-FREKE, STEPHEN
To: NEUTRON LTD.
Reel/Frame 026898/0414 →
Continuity (6)
Continuation In Part 1268623100 · Jan 12, 2010
Continuation In Part 1243365200 · Apr 30, 2009
Provisional Application 6122005500 · Jun 24, 2009
Provisional Application 6104929200 · Apr 30, 2008
Provisional Application 6109480600 · Sep 5, 2008
Related Publication 20100196389A1 · Aug 5, 2010